Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Mar 1;10(18):1664-1666.
doi: 10.18632/oncotarget.26752.

A blast from the past: ROS1 on the brain

Affiliations
Editorial

A blast from the past: ROS1 on the brain

Igor Odintsov et al. Oncotarget. .
No abstract available

Keywords: ROS1; cancer; glioma; inhibitor; kinase.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Genomic alterations identified in brain tumors and potential therapeutic agents
The agents shown here have been tested in various cancer types and the highest stage of clinical trials or FDA approval for any type of tumor is indicated. Only PLB-1001 has been examined specifically in glioblastoma patients. Additional clinical studies are needed to assess the efficacy of many of these agents in the brain. $ For BRAF V600E mutants. No current FDA-approved therapy for RAF fusions. # RAF drugs which block RAF dimerization are likely to act on fusions but clinical activity not published to date. ^Breakthrough designation indicates FDA signal to expedite the development given promising preliminary signs of clinical efficacy.

References

    1. Ostrom QT, et al. Neuro Oncol. 2016;18:v1–75. - PMC - PubMed
    1. Charest A, et al. Cancer Res. 2006;66:7473–81. - PubMed
    1. Singh D, et al. Science. 2012;337:1231–5. - PMC - PubMed
    1. Fasano O, et al. Mol Cell Biol. 1984;4:1695–705. - PMC - PubMed
    1. Birchmeier C, et al. Mol Cell Biol. 1986;6:3109–16. - PMC - PubMed

Publication types